唾液酸结合免疫球蛋白型凝集素-9 在恶性肿瘤发生发展中的作用研究进展

鲁璐 ,  杨露 ,  李娜

大连医科大学学报 ›› 2026, Vol. 48 ›› Issue (3) : 259 -264.

PDF (503KB)
大连医科大学学报 ›› 2026, Vol. 48 ›› Issue (3) : 259 -264. DOI: 10.11724/jdmu.2026.03.10
综述

唾液酸结合免疫球蛋白型凝集素-9 在恶性肿瘤发生发展中的作用研究进展

作者信息 +

Research progress on the role of Siglec-9 in the occurrence and development of malignant tumors

Author information +
文章历史 +
PDF (514K)

摘要

唾液酸结合免疫球蛋白型凝集素(Siglec)家族是一类能够识别唾液酸化聚糖结构的膜蛋白,在巨噬细胞、自然杀伤(NK)细胞和 T 细胞等多种免疫细胞上高表达。近年来,随着对 Siglec 调节肿瘤微环境研究的逐步深入,该家族已成为抗肿瘤药物研发的一个重要方向。Siglec-9 是 Siglec 家族成员之一,属于免疫抑制性唾液酸结合受体。在肿瘤微环境、自身免疫性疾病及感染性疾病中,其在免疫细胞膜表面的表达显著增高。Siglec-9 通过与相应配体结合,调控肿瘤生长和炎症反应,这一特性使其成为抗肿瘤治疗的潜在靶点。

Abstract

The sialic acid-binding immunoglobulin-type lectin (Siglec) family comprises membrane proteins that recognize sialylated glycan structures and is highly expressed on innate immune cells such as macrophages, natural killer (NK) cells, and T cells. In recent years, with increasing research on the role of Siglecs in modulating the tumor microenvironment, they have emerged as important targets for anti-tumor drug development. Siglec-9, a member of the Siglec family, is an immuno-suppressive sialic acid-binding receptor. Its expression is significantly upregulated on immune cells in the tumor micro-environment, as well as in autoimmune and infectious diseases. By binding to its corresponding ligands, Siglec-9 regulates tumor growth and inflammatory responses, making it a potential target for tumor-targeted therapy. This review summarizes the role of Siglec-9 in the development of malignant tumors, aiming to provide new insights and strategies for tumor immun-otherapy.

关键词

Siglec-9 / 肿瘤免疫治疗 / 免疫调节

Key words

Siglec-9 / tumor immunotherapy / immunomodulation

引用本文

引用格式 ▾
鲁璐,杨露,李娜. 唾液酸结合免疫球蛋白型凝集素-9 在恶性肿瘤发生发展中的作用研究进展[J]. 大连医科大学学报, 2026, 48(3): 259-264 DOI:10.11724/jdmu.2026.03.10

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Zhou BQ, Liu JX, Lin MA, et al. Recent advances in immunotherapy, immunoadjuvant, and nanomaterial-based combination immunotherapy[J]. Coord Chem Rev, 2021, 442: 214009. DOI: 10.1016/j.ccr.2021.214009.

[2]

Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age[J]. Nature, 2011, 480(7378): 480-489. DOI: 10.1038/nature10673.

[3]

Sanmamed MF, Chen LP. A paradigm shift in cancer immunotherapy: from enhancement to normalization[J]. Cell, 2018, 175(2): 313-326. DOI: 10.1016/j.cell.2018.09.035.

[4]

Daly J, Carlsten M, O'Dwyer M. Sugar free: novel immunotherapeutic approaches targeting siglecs and sialic acids to enhance natural killer cell cytotoxicity against cancer[J]. Front Immunol, 2019, 10: 1047. DOI: 10.3389/fimmu.2019.01047.

[5]

Büll C, den Brok MH, Adema GJ. Sweet escape: sialic acids in tumor immune evasion[J]. Biochim Biophys Acta BBA Rev Cancer, 2014, 1846(1): 238-246. DOI: 10.1016/j.bbcan.2014.07.005.

[6]

Varki A. Letter to the Glyco-Forum: since there are PAMPs and DAMPs, there must be SAMPs Glycan "self-associated molecular patterns" dampen innate immunity, but pathogens can mimic them[J]. Glycobiology, 2011, 21(9): 1121-1124. DOI: 10.1093/glycob/cwr087.

[7]

Feng HK, Feng JL, Han X, et al. The potential of siglecs and sialic acids as biomarkers and therapeutic targets in tumor immunotherapy[J]. Cancers, 2024, 16(2): 289. DOI: 10.3390/cancers16020289.

[8]

Krishnamoorthy V, Daly J, Kim J, et al. The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9[J]. Leukemia, 2025, 39(2): 346-359. DOI: 10.1038/s41375-024-02454-w.

[9]

van de Wall S, Santegoets KCM, van Houtum EJH, et al. Sialoglycans and siglecs can shape the tumor immune microenvironment[J]. Trends Immunol, 2020, 41(4): 274-285. DOI: 10.1016/j.it.2020.02.001.

[10]

Büll C, Heise T, Adema GJ, et al. Sialic acid mimetics to target the sialic acid-siglec axis[J]. Trends Biochem Sci, 2016, 41(6): 519-531. DOI: 10.1016/j.tibs.2016.03.007.

[11]

van der Haar Àvila I, Zhang T, Lorrain V, et al. Tumor desialylation surpasses anti-PD-L1 checkpoint therapy in restoring anti-tumor immunity in a murine model for colorectal cancer[J]. Int J Cancer, 2025, 157(9): 1948-1962. DOI: 10.1002/ijc.70031.

[12]

Büll C, Boltje TJ, Balneger N, et al. Sialic acid blockade suppresses tumor growth by enhancing T-cell-mediated tumor immunity[J]. Cancer Res, 2018, 78(13): 3574-3588. DOI: 10.1158/0008-5472.can-17-3376.

[13]

Angata T, Varki A. Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways[J]. J Biol Chem, 2000, 275(29): 22127-22135. DOI: 10.1074/jbc.M002775200.

[14]

Läubli H, Varki A. Disrupting Siglec-mediated interactions to develop immunotherapies for cancer treatment[J]. Expert Opin Ther Targets, 2025, 29(9): 613-619. DOI: 10.1080/14728222.2025.2557281.

[15]

Von Gunten S, Bochner BS. Basic and clinical immunology of siglecs[J]. Ann N Y Acad Sci, 2008, 1143(1): 61-82. DOI: 10.1196/annals.1443.011.

[16]

Pillai S, Netravali IA, Cariappa A, et al. Siglecs and immune regulation[J]. Annu Rev Immunol, 2012, 30: 357-392. DOI: 10.1146/annurev-immunol-020711-075018.

[17]

Chen Y, Chen H, Zheng QL. Siglecs family used by pathogens for immune escape may engaged in immune tolerance in pregnancy[J]. J Reprod Immunol, 2023, 159: 104127. DOI: 10.1016/j.jri.2023.104127.

[18]

Bärenwaldt A, Läubli H. The sialoglycan-Siglec glyco-immune checkpoint-a target for improving innate and adaptive anticancer immunity[J]. Expert Opin Ther Targets, 2019, 23(10): 839-853. DOI: 10.1080/14728222.2019.1667977.

[19]

Wieboldt R, Sandholzer M, Carlini E, et al. Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2 [J]. Cell Mol Immunol, 2024, 21(5): 495-509. DOI: 10.1038/s41423-024-01142-0.

[20]

O'Sullivan JA, Youngblood BA, Schleimer RP, et al. Siglecs as potential targets of therapy in human mast cell- and/or eosinophil-associated diseases[J]. Semin Immunol, 2023, 69: 101799. DOI: 10.1016/j.smim.2023.101799.

[21]

Zhang JQ, Nicoll G, Jones C, et al. Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes[J]. J Biol Chem, 2000, 275(29): 22121-22126. DOI: 10.1074/jbc.M002788200.

[22]

Avril T, Floyd H, Lopez F, et al. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by siglecs-7 and-9, CD33-related siglecs expressed on human monocytes and NK cells[J]. J Immunol, 2004, 173(11): 6841-6849. DOI: 10.4049/jimmunol.173.11.6841.

[23]

Yu YY, Peng WJ. Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy[J]. Cancer Biol Med, 2023: 1-16. DOI: 10.20892/j.issn.2095-3941.2023.0046.

[24]

Jiang KY, Qi LL, Kang FB, et al. The intriguing roles of Siglec family members in the tumor microenvironment[J]. Biomark Res, 2022, 10(1): 22. DOI: 10.1186/s40364-022-00369-1.

[25]

Beatson R, Graham R, Grundland Freile F, et al. Cancer-associated hypersialylated MUC1 drives the differentiation of human monocytes into macrophages with a pathogenic phenotype[J]. Commun Biol, 2020, 3: 644. DOI: 10.1038/s42003-020-01359-5.

[26]

Dang Cao TL, Kawanishi K, Hashimoto S, et al. Tumor-expressed GPNMB orchestrates Siglec-9 +TAM polarization and EMT to promote metastasis in triple-negative breast cancer[J]. Proc Natl Acad Sci U S A, 2025, 122(36): e2503081122. DOI: 10.1073/pnas.2503081122.

[27]

Xiao R, Tian Y, Zhang JW, et al. Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy[J]. J Hepatol, 2024, 80(5): 792-804. DOI: 10.1016/j.jhep.2024.01.028.

[28]

Xiao H, Woods EC, Vukojicic P, et al. Precision glycocalyx editing as a strategy for cancer immunotherapy[J]. Proc Natl Acad Sci U S A, 2016, 113(37): 10304-10309. DOI: 10.1073/pnas.1608069113.

[29]

Nicoll G, Ni J, Liu D, et al. Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes[J]. J Biol Chem, 1999, 274(48): 34089-34095. DOI: 10.1074/jbc.274.48.34089.

[30]

Bordoloi D, Kulkarni AJ, Adeniji OS, et al. Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers[J]. Sci Adv, 2023, 9(44): eadh4379. DOI: 10.1126/sciadv.adh4379.

[31]

Rosenstock P, Kaufmann T. Sialic acids and their influence on human NK cell function[J]. Cells, 2021, 10(2): 263. DOI: 10.3390/cells10020263.

[32]

Wang C, Hou YQ, Zak J, et al. 579 Siglec-7/9 receptors suppress T cell immunity via trogocytosis and represent degradable targets for cancer immunotherapy [C]// Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd, 2024: A660- A660. DOI: 10.1136/jitc-2024-sitc2024.0579.

[33]

Stanczak MA, Siddiqui SS, Trefny MP, et al. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells[J]. J Clin Investig, 2018, 128(11): 4912-4923. DOI: 10.1172/jci120612.

[34]

Mei Y, Wang XM, Zhang J, et al. Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response[J]. Nat Cancer, 2023, 4(9): 1273-1291. DOI: 10.1038/s43018-023-00598-9.

[35]

Haas Q, Boligan KF, Jandus C, et al. Siglec-9 regulates an effector memory CD8 + T-cell subset that congregates in the melanoma tumor microenvironment[J]. Cancer Immunol Res, 2019, 7(5): 707-718. DOI: 10.1158/2326-6066.cir-18-0505.

[36]

Wen RM, Stark JC, Marti GEW, et al. Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer[J]. J Clin Invest, 2024, 134(24): e180282. DOI: 10.1172/JCI180282.

[37]

Wen R, Marti GE, Stark J, et al. Abstract 7524: targeting siglec-7/9 glyco-immune checkpoints in prostate cancer for enhanced immune responses and tumor suppression[J]. Cancer Res, 2024, 84(6_Supplement): 7524. DOI: 10.1158/1538-7445.am2024-7524.

[38]

Belisle JA, Horibata S, Jennifer GA, et al. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes[J]. Mol Cancer, 2010, 9(1): 118. DOI: 10.1186/1476-4598-9-118.

[39]

Beatson R, Tajadura-Ortega V, Achkova D, et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9[J]. Nat Immunol, 2016, 17(11): 1273-1281. DOI: 10.1038/ni.3552.

[40]

Cascio S, Finn O. Intra- and extra-cellular events related to altered glycosylation of MUC1 promote chronic inflammation, tumor progression, invasion, and metastasis[J]. Biomolecules, 2016, 6(4): 39. DOI: 10.3390/biom6040039.

[41]

Tomioka Y, Morimatsu M, Nishijima KI, et al. A soluble form of Siglec-9 provides an antitumor benefit against mammary tumor cells expressing MUC1 in transgenic mice[J]. Biochem Biophys Res Commun, 2014, 450(1): 532-537. DOI: 10.1016/j.bbrc.2014.06.009.

[42]

Tanida S, Akita K, Ishida A, et al. Binding of the sialic acid-binding lectin, siglec-9, to the membrane mucin, MUC1, induces recruitment of β-catenin and subsequent cell growth[J]. J Biol Chem, 2013, 288(44): 31842-31852. DOI: 10.1074/jbc.M113.471318.

[43]

Zhao SS, Bordoloi D, Ionescu C, et al. Abstract LB211: development of novel immune checkpoint inhibitor: anti-siglec-9 antibody[J]. Cancer Res, 2025, 85(8_Supplement_2): LB211. DOI: 10.1158/1538-7445.am2025-lb211.

[44]

Ibarlucea-Benitez I, Weitzenfeld P, Smith P, et al. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity [J]. Proc Natl Acad Sci U S A, 2021, 118(26): e2107424118. DOI: 10.1073/pnas.2107424118.

[45]

Choi H, Ho M, Adeniji OS, et al. Development of siglec-9 blocking antibody to enhance anti-tumor immunity[J]. Front Oncol, 2021, 11: 778989. DOI: 10.3389/fonc.2021.778989.

[46]

Li GZ, Zhang KN, Wang Z, et al. Siglecs, novel immunotherapy targets, potentially enhance the effectiveness of existing immune checkpoint inhibitors in glioma immunotherapy[J]. OncoTargets Ther, 2019, 12: 10263-10273. DOI: 10.2147/OTT.S223406.

[47]

Wang C. Abstract B045: Siglec receptors suppress T cell immunity via trogocytosis and represent degradable targets for cancer immunotherapy [J]. Cancer Immunol Res, 2025, 13(2_Supplement): B045. DOI: 10.1158/2326-6074.io2025-b045.

[48]

Huang JM, Huang JM, Zhang GN. Insights into the role of sialylation in cancer metastasis, immunity, and therapeutic opportunity[J]. Cancers, 2022, 14(23): 5840. DOI: 10.3390/cancers14235840.

[49]

Toussaint K, Appert-Collin A, Morjani H, et al. Neuraminidase-1: a sialidase involved in the development of cancers and metabolic diseases[J]. Cancers, 2022, 14(19): 4868. DOI: 10.3390/cancers14194868.

[50]

Jandus C, Boligan KF, Chijioke O, et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance[J]. J Clin Invest, 2014, 124(4): 1810-1820. DOI: 10.1172/jci65899.

[51]

Gray MA, Stanczak MA, Mantuano NR, et al. Targeted glycan degradation potentiates the anticancer immune response in vi- vo [J]. Nat Chem Biol, 2020, 16(12): 1376-1384. DOI: 10.1038/s41589-020-0622-x.

[52]

Stanczak MA, Rodrigues Mantuano N, Kirchhammer N, et al. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade[J]. Sci Transl Med, 2022, 14(669): eabj1270. DOI: 10.1126/scitranslmed.abj1270.

[53]

Behrens LM, van den Berg TK, van Egmond M. Targeting the CD47-SIRPα innate immune checkpoint to potentiate antibody therapy in cancer by neutrophils[J]. Cancers, 2022, 14(14): 3366. DOI: 10.3390/cancers14143366.

[54]

Chan C, Lustig M, Marco Jansen JH, et al. Sialic acids on tumor cells modulate IgA therapy by neutrophils via inhibitory receptors siglec-7 and siglec-9 [J]. Cancers, 2023, 15(13): 3405. DOI: 10.3390/cancers15133405.

[55]

陈启航, 魏湲颜, 江建海. Siglecs 介导肿瘤免疫逃逸的研究进展[J]. 生命的化学, 2021, 41(4): 756-761. DOI: 10.13488/j.smhx.20200587.

[56]

Hornikx DLAH, Visser EA, Psomiadou V, et al. Engineering the sialome of mammalian cells with sialic acid mimetics[J]. STAR Protoc, 2023, 4(3): 102330. DOI: 10.1016/j.xpro.2023.102330.

[57]

Eisenberg V, Hoogi S, Katzman E, et al. Targeting tumor-associated sialic acids using chimeric switch receptors based on siglec-9 enhances the antitumor efficacy of engineered T cells[J]. Cancer Immunol Res, 2024, 12(10): 1380-1391. DOI: 10.1158/2326-6066.CIR-23-0823.

基金资助

四川省科技计划项目(2023YFS0488)

AI Summary AI Mindmap
PDF (503KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉